A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407.

[1]  Jianying Zhou,et al.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial , 2019, The Lancet.

[2]  A. Tafreshi,et al.  Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Tafreshi,et al.  Pembrolizumab plus Chemotherapy for Squamous Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[4]  M. Socinski,et al.  IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. , 2018, Journal of Clinical Oncology.

[5]  Q. Gao,et al.  Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells , 2017, Oncoimmunology.

[6]  C. Gridelli,et al.  Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies , 2017, PloS one.

[7]  P C Lambert,et al.  Adjusting for treatment switching in randomised controlled trials – A simulation study and a simplified two-stage method , 2017, Statistical methods in medical research.

[8]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[9]  S. Scarpace.  Metastatic squamous cell non-small-cell lung cancer (NSCLC): disrupting the drug treatment paradigm with immunotherapies , 2015, Drugs in context.

[10]  K. D. de Visser,et al.  Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy , 2015, Front. Immunol..

[11]  G. Coukos,et al.  Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  C. Schumann,et al.  Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. , 2015, The Lancet. Oncology.

[13]  A. Oza,et al.  Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials , 2015, Cancer.

[14]  Keith R Abrams,et al.  Adjusting Survival Time Estimates to Account for Treatment Switching in Randomized Controlled Trials—an Economic Evaluation Context , 2014, Medical decision making : an international journal of the Society for Medical Decision Making.

[15]  L. Bracci,et al.  Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer , 2013, Cell Death and Differentiation.

[16]  M. Socinski,et al.  Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  I. D. de Vries,et al.  Molecular Pathways Molecular Pathways : The Immunogenic Effects of Platinum-Based Chemotherapeutics , 2014 .

[18]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.